Federal Pharmaceutical (03933.HK) released its interim performance, with shareholder profits of 1.894 billion yuan, an increase of 27% year-on-year.

According to the China Business News app, Federal Pharmaceutical (03933.HK) released its interim performance for the six months ending June 30, 2025. The group achieved revenue of RMB 7.519 billion (unit is the same), an increase of 4.8% year-on-year. The company's attributable profit for the period was RMB 1.894 billion, an increase of 27% year-on-year. Basic earnings per share were 104.26 cents, with a proposed interim dividend of 16 cents per share.